Retinal Vein Occlusion Treatment

Global Retinal Vein Occlusion Treatment Market to Reach US$3.9 Billion by 2030

The global market for Retinal Vein Occlusion Treatment estimated at US$2.8 Billion in the year 2024, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Central Retinal Vein Occlusion, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Branch Retinal Vein Occlusion segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$749.4 Million While China is Forecast to Grow at 9.7% CAGR

The Retinal Vein Occlusion Treatment market in the U.S. is estimated at US$749.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$804.1 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Retinal Vein Occlusion Treatment Market – Key Trends & Drivers Summarized

Why Is Effective Retinal Vein Occlusion (RVO) Treatment Becoming More Important?

Retinal vein occlusion (RVO) is a leading cause of vision impairment, often associated with underlying conditions such as hypertension, diabetes, and cardiovascular diseases. As RVO can lead to severe complications, including macular edema and neovascular glaucoma, the demand for effective treatment strategies has increased. Advances in pharmacotherapy, laser therapy, and surgical interventions have improved patient outcomes, helping to prevent further vision deterioration. The growing aging population, along with the increasing prevalence of metabolic disorders, has contributed to a rise in RVO cases worldwide. As a result, healthcare providers and researchers are focusing on developing more targeted and long-lasting treatment options.

How Are Technological Advancements Improving RVO Treatment Outcomes?

The development of anti-VEGF (vascular endothelial growth factor) therapy has transformed the treatment landscape for RVO-related macular edema, significantly reducing retinal swelling and improving visual acuity. Sustained-release corticosteroid implants have also been introduced, offering long-term benefits with fewer injections. Additionally, advancements in laser photocoagulation techniques, including micropulse laser therapy, have provided more precise treatment options with reduced side effects. AI-powered diagnostic tools and retinal imaging systems are enhancing early detection and personalized treatment planning, ensuring timely interventions for RVO patients. Moreover, emerging regenerative medicine approaches, including stem cell therapy, hold promise for restoring damaged retinal tissues and improving long-term prognosis.

What Market Trends Are Driving the Demand for RVO Treatments?

The increasing adoption of combination therapies, integrating anti-VEGF injections with laser treatments, has enhanced treatment efficacy while reducing the frequency of medical interventions. The expansion of teleophthalmology services has facilitated early diagnosis and remote monitoring, improving patient management. Additionally, the rise of home-based vision monitoring solutions, such as smartphone-based retinal imaging, is empowering patients to track their eye health and seek timely medical attention. Government-funded retinal disease screening programs and healthcare reimbursement policies are further driving market growth. As research continues to explore novel therapeutic approaches, including gene therapy and neuroprotection, the RVO treatment market is evolving rapidly.

What Are the Key Growth Drivers of the RVO Treatment Market?

The growth in the global retinal vein occlusion treatment market is driven by increasing incidences of diabetes and hypertension, advancements in pharmacological therapies, and improvements in retinal imaging technology. The widespread adoption of anti-VEGF therapy as a first-line treatment for RVO-related complications has significantly contributed to market expansion. Additionally, the growing availability of long-acting drug delivery systems is improving patient compliance and reducing treatment burden. The expansion of healthcare access in emerging markets, along with government-led initiatives for vision care, is further accelerating demand. As new therapeutic innovations continue to emerge, the RVO treatment market is expected to witness sustained growth, offering improved solutions for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Retinal Vein Occlusion Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion); Treatment (Anti-vascular Endothelial Factor, Corticosteroid Drugs, Others); End-Use (Hospital & Clinics, Retail Pharmacy, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -
  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Retinal Vein Occlusion Treatment – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Prevalence of Hypertension and Cardiovascular Risk Factors Drives Incidence of Retinal Vein Occlusion
Rising Demand for Anti-VEGF and Corticosteroid Injections Throws the Spotlight on Pharmacologic Management
Expansion of Patient Access to Intravitreal Therapies Strengthens Business Case for RVO Treatment Portfolios
Development of Sustained-Release Implants Enhances Adherence and Reduces Treatment Burden
Clinical Research on Combination Therapies Propels Innovation in Managing Complex and Resistant RVO Cases
Integration of OCT Imaging and Angiography in Diagnostic Pathways Enhances Early Detection and Monitoring
Rising Emphasis on Personalized Therapy Selection Based on Occlusion Type Supports Precision Medicine Approaches
Increased Awareness Campaigns Around Ocular Stroke and Vascular Health Drives Early Intervention Rates
Regulatory Approvals for Long-Acting Formulations and New Drug Classes Expand Therapeutic Options
Expansion of Ophthalmology Clinics and Ambulatory Injection Facilities Accelerates Market Accessibility
Technological Advancements in Intraocular Injection Devices Improve Accuracy and Reduce Complications
Growing Pipeline of Novel Biologics and Biosimilars Enhances Competitive Landscape and Affordability
Inclusion of RVO Treatment in Public Health Eye Screening Programs Broadens Patient Outreach
Use of Adjunctive Laser Therapy in Ischemic RVO Supports Multimodal Treatment Strategies
Rising Research on Inflammation and Microvascular Involvement Spurs New Mechanism-Targeted Drugs
Shift Toward Evidence-Based Retreatment Protocols Improves Long-Term Visual Outcomes
Strategic Collaborations Between Pharma Companies and Retinal Specialists Drive Drug Adoption
Real-World Data and Clinical Registries Strengthen Post-Market Evidence for RVO Therapies
Reimbursement Expansion and Tiered Access Pricing Models Boost Treatment Uptake in Developing Regions
Global Burden of Vision Loss From RVO Accelerates Innovation in Both Diagnostic and Therapeutic Modalities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Retinal Vein Occlusion Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Central Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Branch Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Anti-vascular Endothelial Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospital & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
TABLE 38: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 41: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 47: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Japan Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 56: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: China Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: China 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 59: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: China Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: China 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: China 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 65: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 77: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: France Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: France 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 80: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: France Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: France 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: France 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 86: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Germany Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 89: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
TABLE 95: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Italy Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 98: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 104: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: UK Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 107: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: UK Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
SPAIN
TABLE 113: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Spain Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 116: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Spain Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 119: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
RUSSIA
TABLE 122: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Russia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 125: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Russia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 128: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
AUSTRALIA
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 152: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Australia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 155: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Australia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 158: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
INDIA
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 161: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: India Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: India 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 164: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: India Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: India 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 167: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: India 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 170: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: South Korea Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 173: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: South Korea Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 176: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
LATIN AMERICA
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 188: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 189: Latin America Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 191: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 194: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 200: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Argentina Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 203: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Argentina Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 206: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
BRAZIL
TABLE 209: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Brazil Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 212: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Brazil Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 215: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
MEXICO
TABLE 218: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Mexico Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 221: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Mexico Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 224: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
MIDDLE EAST
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 236: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 237: Middle East Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 239: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 242: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
IRAN
TABLE 248: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Iran Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 251: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Iran Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 254: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
ISRAEL
TABLE 257: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Israel Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 260: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Israel Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 263: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 275: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: UAE Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 278: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: UAE Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 281: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
AFRICA
Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 293: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Africa Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
TABLE 296: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Africa Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
TABLE 299: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings